Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.
Gluck WL, Gounder MM, Frank R, Eskens F, Blay JY, Cassier PA, Soria JC, Chawla S, de Weger V, Wagner AJ, Siegel D, De Vos F, Rasmussen E, Henary HA.
Gluck WL, et al.
Invest New Drugs. 2020 Jun;38(3):831-843. doi: 10.1007/s10637-019-00840-1. Epub 2019 Jul 29.
Invest New Drugs. 2020.
PMID: 31359240
Free PMC article.
Clinical Trial.